Whole-person autoimmune care: WellTheory raises $14 million Series A to build category leader
Investing in AI-enabled personalization, commercial expansion and partnerships
WellTheory, a virtual care platform focused on autoimmune disease, has raised $14 million in Series A funding to invest in its commercial growth, expand its AI capabilities, and scale partnerships with employers and payors.
The round was led by General Catalyst, with participation from 7wire Ventures, Ingeborg Investments, Accel, Box Group, and Up2 Opportunity Fund.
The new capital brings WellTheory’s total funding to $26.2 million.
A fast-growing and expensive category
Autoimmune disease is one of the fastest-growing and most costly areas in healthcare, now affecting more than 50 million Americans and representing a $160 billion market. Its prevalence has also doubled over the last three decades, making it a rising priority for both employers and payors.
Autoimmune disease also disproportionately affects women - up to eighty percent of patients - with certain conditions being 16 times more common in women. In December 2024, WellTheory launched a dedicated women’s health program to support women navigating the link between autoimmune disease and hormone imbalances. At the time it revealed that women made up 71% of WellTheory’s patient population.
Designing for the workforce
Employers and payors are increasingly seeking solutions that improve outcomes while reducing costs - a challenge WellTheory aims to meet through its AI-enabled, whole-person care model.
“WellTheory is building the future of autoimmune care with a model that’s uniquely designed for today’s workforce,” said Ellen Rudolph, CEO and Co-Founder of WellTheory.
“Employers are facing rising costs, while employees wait years for answers on their own health — a frustrating journey I experienced firsthand. By combining high-touch care with AI-enabled personalization, we’re addressing both parties, delivering a better quality of life for patients and measurable cost reductions for employers and payors.”
Expansion and AI integration
The new funding will be used to deepen partnerships with employers and payors, expand care programs targeting high-cost conditions, and invest further in AI-enabled personalization.
“WellTheory is addressing the impact of autoimmune disease by recognizing the important role that diet and lifestyle can play in supporting patients,” said Candace Richardson, partner at General Catalyst, who is joining the company’s board.
“The platform is demonstrating how this kind of support can be delivered at scale, and this is just the beginning. It is expanding to integrate medical treatment and medication management, creating a more comprehensive model designed to improve patient experiences and strengthen system sustainability.”
“WellTheory’s AI-powered, whole-person model is proving it can do both,” added Alyssa Jaffee, partner at 7wire Ventures.
“We are impressed by the company’s ability to deliver meaningful savings for its partners today while also setting a new standard for a personalized, consumer-first experience.”
Rapid commercial traction
In just 18 months on the commercial market, WellTheory has secured partnerships with Fortune 100 and 500 employers and high-growth companies including Maven Clinic, Fortune Brands Innovations, and Dayforce, as well as payors such as Sentara Health Plans and one of the top national insurers.
Independent claims analyses show the platform reduces ER visits, imaging, hospitalizations, and biologics utilization, generating thousands of dollars in annual savings per patient. Over the past year, WellTheory has reported 10× member growth and 5× revenue growth, highlighting both market demand and operational traction.
Women’s health focus and growing demand
At the time of its women’s health program launch in 2024, Ellen reflected on her personal experience, sharing:
“As a woman who began suffering with an autoimmune disease in my mid-20’s, who went on to learn that multiple hormonal issues were one of the root causes of my diagnosis, it was important to create a program aimed at helping other women navigate this oftentimes long and frustrating journey to find solutions.”
Today many of its female members are managing autoimmune conditions alongside hormonal issues such as PCOS, endometriosis, or thyroid disorders. That demographic reality has helped shape the company’s product development and commercial strategy, particularly as employers seek benefits models that address the needs of a female workforce.